Sima Lev’s lab – Combination Therapy & Drug Resistance
Combination Therapy & Drug Resistance TNBC – Triple-Negative Breast Cancer – accounts for approximately 20 percent of all breast cancer patients and can be divided […]
Publications
Accelerating AXL targeting for TNBC therapy Lohit Khera, Sima Lev
First described by electron microscopists in the early 60s the ER-Golgi contact sites in mammalian cells have remained The tyrosine kinase receptor AXL of the […]
The Golgi Apparatus and Membrane Contact Sites
First described by electron microscopists in the early 60s the ER-Golgi contact sites in mammalian cells have remained unexplored for forty years when the discovery […]
Targeted therapy and drug resistance in triple-negative breast cancer: the EGFR axis
Sima Lev – Molecular Cell Biology Department, Weizmann Institute of Science, Rehovot (sima.lev@weizmann.ac.il) Targeting of estrogen receptor is commonly used as afirst-line treatment for hormone-positive […]
